QED Therapeutics

What QED Therapeutics does

QED Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for FGFR3-driven skeletal dysplasias, with achondroplasia as its lead indication. Founded in 2018 and headquartered in Palo Alto, California, QED operates as a focused subsidiary of BridgeBio Pharma and is advancing oral infigratinib, a small-molecule FGFR3 inhibitor that addresses the genetic root cause of achondroplasia by reducing the overactive FGFR3 signaling responsible for impaired bone growth. The program has been studied in the PROPEL and PROPEL 2 pediatric trials and received FDA Breakthrough Therapy Designation in September 2024.

QED's product portfolio is concentrated around a single therapeutic candidate; oral infigratinib is the company's defining asset and the basis of its regulatory and clinical strategy. The company does not have commercialized products and has not disclosed pricing, distribution, or marketing infrastructure. End users are pediatric patients with achondroplasia and related FGFR3-driven skeletal disorders, a rare-disease population of approximately 1 in 25,000 births.

The business model is pre-revenue and oriented around clinical development milestones funded by BridgeBio, with a $65 million capital commitment recorded at founding in 2018. Revenue mechanics are not yet established; future commercialization would rely on standard pharmaceutical supply chains and rare-disease specialty distribution upon regulatory approval. Operating leverage depends on continued BridgeBio support, regulatory advancement of infigratinib, and potential label expansion into adjacent indications such as hypochondroplasia.

Name

QED Therapeutics

Legal name

BridgeBio Pharma, Inc.

Website

https://qedtx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

QED Therapeutics is a clinical-stage biopharmaceutical subsidiary of BridgeBio Pharma developing oral infigratinib, an FGFR3 inhibitor for achondroplasia and related skeletal dysplasias. The company is pre-revenue and headquartered in Palo Alto, California.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics / Precision Medicine Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• FGFR3 inhibitor therapy
• Rare disease therapeutics
• Skeletal dysplasia treatment
• Precision medicine biotechnology
• Achondroplasia drug development

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical product revenue (future): QED Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for FGFR3-related disorders including achondroplasia. The company does not yet have commercialized products and is pre-revenue.

Core offering

QED Therapeutics is a clinical-stage biopharmaceutical company developing targeted precision medicines for FGFR3-driven disorders, with a primary focus on oral infigratinib for achondroplasia. The company's lead investigational therapy received FDA Breakthrough Therapy Designation in September 2024 and is being evaluated in the PROPEL and PROPEL 2 clinical trials in children with achondroplasia.

Product overview

BridgeBio Pharma is a biopharmaceutical company focused on genetic diseases, with clinical programs targeting FGFR3-related disorders including achondroplasia. The company operates a pipeline of programs across multiple genetic conditions. The primary product/program referenced in the source data is infigratinib, an oral FGFR3 inhibitor being studied in PROPEL and PROPEL 2 clinical trials for achondroplasia.

Differentiator

Problem solved

Functional benefit

Products and services

• Infigratinib (oral FGFR3 inhibitor for achondroplasia) An oral FGFR3 inhibitor being developed for the treatment of achondroplasia, the most common type of skeletal dysplasia caused by a change in the FGFR3 gene. The therapy targets FGFR3 overactivity to restore bone growth and is intended for children and adults with achondroplasia.

Quantifiable outcome

• FGFR3 becomes overactive in achondroplasia, which reduces bone growth and leads to common features of achondroplasia

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• BridgeBio PharmacoreStrategic or Co-development PartnerQED Therapeutics is a subsidiary of BridgeBio Pharma, focused on developing targeted therapies for FGFR3-related disorders. BridgeBio provides research infrastructure, clinical trial capabilities, and regulatory expertise.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• BioMarin Pharmaceutical: BioMarin markets Voxzogo (vosoritide), the only FDA-approved therapy for achondroplasia. It is the most direct competitor to QED's infigratinib, competing for the same patient population with an established C-type natriuretic peptide analog requiring daily subcutaneous injection.
• Ascendis Pharma: Ascendis is developing TransCon CNP (palopegteriparatide) for achondroplasia, a prodrug CNP analog with weekly dosing. As another late-stage therapeutic in the same indication, it directly competes with both QED's infigratinib and BioMarin's vosoritide for market share.

Broad incumbents

• BridgeBio Pharma: BridgeBio is QED's parent company and operates a broad pipeline of genetic disease therapies including approved products Attruby and Nulibry. While not a direct competitor, BridgeBio's infrastructure, capital allocation, and portfolio strategy directly shape QED's clinical development and commercialization pathway.
• Pfizer: Pfizer originally developed infigratinib (BGJ398) for oncology indications before BridgeBio's QED repurposed it for achondroplasia. Pfizer is also a rare-disease player with prior achondroplasia R&D exposure through its Therachon acquisition and broader gene therapy and rare disease portfolio.
• Alexion (AstraZeneca Rare Disease): Alexion is a major rare disease franchise within AstraZeneca with deep commercialization infrastructure for orphan therapeutics. As a potential acquirer of late-stage rare disease assets and competitor for rare-disease physician relationships, it is highly relevant to QED's commercial pathway and strategic optionality.
• Takeda Pharmaceutical: Takeda has an active rare disease and rare hematology/skeletal franchise and is a typical acquirer of late-stage rare disease assets with global commercialization reach. Its rare disease commercial infrastructure and capital capacity make it a relevant peer for strategic considerations.

Emerging players

• Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease biotech developing therapies for skeletal and metabolic disorders, with overlapping expertise in conditions affecting bone growth and rare pediatric populations. Its focus on enzyme replacement and gene therapies for rare skeletal conditions makes it a relevant emerging peer.
• Crinetics Pharmaceuticals: Crinetics develops oral small molecule therapies targeting rare endocrine disorders, with parallel expertise in developing targeted oral therapies for underserved rare conditions. Its novel oral approach to hormone-driven rare diseases parallels QED's strategy of bringing oral targeted therapy to achondroplasia.
• Ipsen: Ipsen has a growing rare disease and rare skeletal disorder franchise through its acquisition of rare bone disease assets. Its interest in rare pediatric and skeletal conditions makes it a relevant peer for both competitive dynamics and potential partnership/acquisition scenarios.
• Therachon (acquired by Pfizer): Therachon was a clinical-stage biotech developing TA-46 (recifercept) for achondroplasia before being acquired by Pfizer in 2019. Its prior competitive positioning in achondroplasia and continued development under Pfizer makes it a historical peer whose trajectory informs QED's strategic options.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/BridgeBioPharma
• YouTubeyoutube.com/@BridgeBioPharma
• Facebookfacebook.com/bridgebiopharma
• LinkedInlinkedin.com/company/bridgebio
• Instagraminstagram.com/bridgebiopharma
• TikToktiktok.com/@bridgebiopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QED Therapeutics